S2E7 - APTT, not a one-for-all-purposes reagent - a podcast by Stago

from 2021-03-30T07:00

:: ::

Welcome to Ask Stago, the Podcast dedicated to provide expert answers to your expert questions in coagulation. In today episode, our expert Thomas, is covering with us the usages of APTT testing.  


 


Literature sources: 


  • Toulon, P., Eloit, Y., Smahi, M., Sigaud, C., Jambou, D., Fischer, F. and Appert?Flory, A. (2016), In vitro sensitivity of different activated partial thromboplastin time reagents to mild clotting factor deficiencies. Int. Jnl. Lab. Hem., 38: 389-396. https://doi.org/10.1111/ijlh.12499


  • CLSI One-stage Prothrombin Time (PT) test and Activated Partial Thromboplastin Time (APTT) test; Approved guideline - second edition. CLSI document H47-A2 Wayne, PA: Clinical and Laboratory Standard Institute, 2008 


  • Levy JH, Szlam F, Wolberg AS, Winkler A. Clinical use of the activated partial thromboplastin time and prothrombin time for screening: a review of the literature and current guidelines for testing. Clin Lab Med. 2014 Sep;34(3):453-77. doi: 10.1016/j.cll.2014.06.005 


  • Kitchen S, Jennings I, Woods TA, Preston FE. Wide variability in the sensitivity of APTT reagents for monitoring of heparin dosage. J Clin Pathol. 1996 Jan;49(1):10-4. doi: 10.1136/jcp.49.1.10. 


  • Gosselin RC, King JH, Janatpour KA, Dager WE, Larkin EC, Owings JT. Comparing direct thrombin inhibitors using aPTT, ecarin clotting times, and thrombin inhibitor management testing. Ann Pharmacother. 2004 Sep;38(9):1383-8. doi: 10.1345/aph.1D565. 


  • Gouin-Thibaut I, Martin-Toutain I, Peynaud-Debayle E, et al. Monitoring unfractionated heparin with APTT: a French collaborative study comparing sensitivity to heparin of 15 APTT reagents. Thrombosis Research. 2012 May;129(5):666-667. DOI: 10.1016/j.thromres.2011.11.016. 


  • Triplett DA. Screening for the lupus anticoagulant. Ricerca in Clinica E in Laboratorio. 1989; 19-379-89 


  • Denis-Magdelaine A et al; Sensitivity of sixteen APTT reagents for the presence of anticoagulant. Haemostasis 1995; 25:98-105/ 


  • Rozen L, Copette F, Noubouossie DF, Demulder A. Evaluation of three APTT reagents in a routine laboratory: toward a compromise. Clin Lab. 2013;59(7-8):921-4. doi: 10.7754/clin.lab.2012.120909 


  • van Rossum, A.P., Vlasveld, L.T., van den Hoven, L.J.M., de Wit, C.W.M. and Castel, A. (2012), False prolongation of the activated partial thromboplastin time (aPTT) in inflammatory patients: interference of C?reactive protein. Br J Haematol, 157: 394-395. https://doi.org/10.1111/j.1365-2141.2011.08990.x 


  • Gu, J.?M., Ramsey, P., Evans, V., Tang, L., Apeler, H., Leong, L., Murphy, J.E., Laux, V. and Myles, T. (2014), Evaluation of the activated partial thromboplastin time assay for clinical monitoring of PEGylated recombinant factor VIII (BAY 94?9027) for haemophilia A. Haemophilia, 20: 593-600. https://doi.org/10.1111/hae.12374


  • Hillarp A, Bowyer A, Ezban M, Persson P, Kitchen S. Measuring FVIII activity of glycopegylated recombinant factor VIII, N8-GP, with commercially available one-stage clotting and chromogenic assay kits: a two-centre study. Haemophilia. 2017 May;23(3):458-465. doi: 10.1111/hae.13168. 


  • Ezban M, Hansen M, Kjalke M. An overview of turoctocog alfa pegol (N8-GP; ESPEROCT® ) assay performance: Implications for postadministration monitoring. Haemophilia. 2020;26(1):156-163. doi:10.1111/hae.13897 




Related podcasts: 




____________________________________________________________________________________________________________


Content is scientific and technical in nature. It is intended as an educational tool for laboratory professionals and topics discussed are not intended as recommendations or as commentary on appropriate clinical practice. 


Further episodes of Ask Stago (english version)

Further podcasts by Stago

Website of Stago